{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:22:24Z","timestamp":1787829744673,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000947","name":"Australian Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000947","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Macquarie University Research Acceleration Scheme"},{"DOI":"10.13039\/501100006641","name":"Cure Brain Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006641","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021954","name":"Tour De Cure","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01537-4","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:42:48Z","timestamp":1780123368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinctive features of the tumor and immune microenvironment in glioblastoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Elena","family":"Shklovskaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Yin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mal","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia V.","family":"Pinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brindha","family":"Shivalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laveniya","family":"Satgunaseelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley L.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Ieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Yen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"1537_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1537_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127\u2013137 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1537_CR3","doi-asserted-by":"publisher","unstructured":"Long, G. V. et al. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03512-1 (2025).","DOI":"10.1038\/s41591-025-03512-1"},{"key":"1537_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 25, 123\u2013134 (2023).","journal-title":"Neuro Oncol."},{"key":"1537_CR5","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24, 1935\u20131949 (2022).","journal-title":"Neuro Oncol."},{"key":"1537_CR6","doi-asserted-by":"publisher","unstructured":"Pombo Antunes, A. R. et al. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife. https:\/\/doi.org\/10.7554\/eLife.52176 (2020).","DOI":"10.7554\/eLife.52176"},{"key":"1537_CR7","volume":"5","author":"P Sharma","year":"2023","unstructured":"Sharma, P., Aaroe, A., Liang, J. & Puduvalli, V. K. Tumor microenvironment in glioblastoma: current and emerging concepts. Neurooncol. Adv. 5, vdad009 (2023).","journal-title":"Neurooncol. Adv."},{"key":"1537_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.immuni.2025.04.017","volume":"58","author":"KW Song","year":"2025","unstructured":"Song, K. W., Lim, M. & Monje, M. Complex neural-immune interactions shape glioma immunotherapy. Immunity 58, 1140\u20131160 (2025).","journal-title":"Immunity"},{"key":"1537_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","volume":"26","author":"GV Long","year":"2025","unstructured":"Long, G. V. et al. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 26, 320\u2013330 (2025).","journal-title":"Lancet Oncol."},{"key":"1537_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg, S. B. et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 21, 655\u2013663 (2020).","journal-title":"Lancet Oncol."},{"key":"1537_CR11","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.3390\/cancers12113374","volume":"12","author":"E Shklovskaya","year":"2020","unstructured":"Shklovskaya, E. et al. Tumor MHC expression guides first-line immunotherapy selection in melanoma. Cancers 12, 3374 (2020).","journal-title":"Cancers"},{"key":"1537_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15726-7","volume":"11","author":"JH Lee","year":"2020","unstructured":"Lee, J. H. et al. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nat. Commun. 11, 1897 (2020).","journal-title":"Nat. Commun."},{"key":"1537_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1537_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ng.127","volume":"40","author":"I Ben-Porath","year":"2008","unstructured":"Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet 40, 499\u2013507 (2008).","journal-title":"Nat. Genet"},{"key":"1537_CR15","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1101\/gad.261982.115","volume":"29","author":"JD Lathia","year":"2015","unstructured":"Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. & Rich, J. N. Cancer stem cells in glioblastoma. Genes Dev. 29, 1203\u20131217 (2015).","journal-title":"Genes Dev."},{"key":"1537_CR16","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.18632\/oncotarget.3365","volume":"6","author":"DV Brown","year":"2015","unstructured":"Brown, D. V. et al. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Oncotarget 6, 6267\u20136280 (2015).","journal-title":"Oncotarget"},{"key":"1537_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36979-y","volume":"14","author":"SY Lim","year":"2023","unstructured":"Lim, S. Y. et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nat. Commun. 14, 1516 (2023).","journal-title":"Nat. Commun."},{"key":"1537_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm5214","volume":"387","author":"C Jackson","year":"2025","unstructured":"Jackson, C. et al. Distinct myeloid-derived suppressor cell populations in human glioblastoma. Science 387, eabm5214 (2025).","journal-title":"Science"},{"key":"1537_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41277-z","volume":"9","author":"BW Stringer","year":"2019","unstructured":"Stringer, B. W. et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. Sci. Rep. 9, 4902 (2019).","journal-title":"Sci. Rep."},{"key":"1537_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 7, 188\u2013201 (2017).","journal-title":"Cancer Discov."},{"key":"1537_CR21","doi-asserted-by":"publisher","first-page":"64892","DOI":"10.18632\/oncotarget.17615","volume":"8","author":"S Jutz","year":"2017","unstructured":"Jutz, S. et al. A cellular platform for the evaluation of immune checkpoint molecules. Oncotarget 8, 64892\u201364906 (2017).","journal-title":"Oncotarget"},{"key":"1537_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47910-1","volume":"9","author":"A De Sousa Linhares","year":"2019","unstructured":"De Sousa Linhares, A. et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling. Sci. Rep. 9, 11472 (2019).","journal-title":"Sci. Rep."},{"key":"1537_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/cancers5020357","volume":"5","author":"BW Day","year":"2013","unstructured":"Day, B. W. et al. Glioma surgical aspirate: a viable source of tumor tissue for experimental research. Cancers 5, 357\u2013371 (2013).","journal-title":"Cancers"},{"key":"1537_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fsurg.2016.00011","volume":"3","author":"SM Razavi","year":"2016","unstructured":"Razavi, S. M. et al. Immune evasion strategies of glioblastoma. Front Surg. 3, 11 (2016).","journal-title":"Front Surg."},{"key":"1537_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65915-z","volume":"10","author":"Y Fu","year":"2020","unstructured":"Fu, Y. et al. GATA2 regulates constitutive PD-L1 and PD-L2 expression in brain tumors. Sci. Rep. 10, 9027 (2020).","journal-title":"Sci. Rep."},{"key":"1537_CR26","doi-asserted-by":"publisher","first-page":"e1541535","DOI":"10.1080\/2162402X.2018.1541535","volume":"8","author":"ZL Wang","year":"2019","unstructured":"Wang, Z. L. et al. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. Oncoimmunology 8, e1541535 (2019).","journal-title":"Oncoimmunology"},{"key":"1537_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860640","volume":"12","author":"Q Xie","year":"2022","unstructured":"Xie, Q., Huang, X., Huang, W. & Liu, F. PD-L2 serves as a potential prognostic biomarker that correlates with immune infiltration and may predict therapeutic sensitivity in lower-grade gliomas. Front Oncol. 12, 860640 (2022).","journal-title":"Front Oncol."},{"key":"1537_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s42003-021-02111-3","volume":"4","author":"T Takehara","year":"2021","unstructured":"Takehara, T. et al. PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment. Commun. Biol. 4, 581 (2021).","journal-title":"Commun. Biol."},{"key":"1537_CR29","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.molimm.2011.06.436","volume":"48","author":"N Messal","year":"2011","unstructured":"Messal, N., Serriari, N. E., Pastor, S., Nunes, J. A. & Olive, D. PD-L2 is expressed on activated human T cells and regulates their function. Mol. Immunol. 48, 2214\u20132219 (2011).","journal-title":"Mol. Immunol."},{"key":"1537_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49\u201361 (2014).","journal-title":"Immunity"},{"key":"1537_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07191-7","volume":"15","author":"T Liu","year":"2024","unstructured":"Liu, T. et al. PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function. Cell Death Dis. 15, 800 (2024).","journal-title":"Cell Death Dis."},{"key":"1537_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.4049\/jimmunol.1101412","volume":"188","author":"R Gary","year":"2012","unstructured":"Gary, R. et al. Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis. J. Immunol. 188, 744\u2013752 (2012).","journal-title":"J. Immunol."},{"key":"1537_CR33","doi-asserted-by":"publisher","first-page":"11771","DOI":"10.1074\/jbc.M112.448126","volume":"288","author":"X Cheng","year":"2013","unstructured":"Cheng, X. et al. Structure and interactions of the human programmed cell death 1 receptor. J. Biol. Chem. 288, 11771\u201311785 (2013).","journal-title":"J. Biol. Chem."},{"key":"1537_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jmgm.2015.01.015","volume":"57","author":"C Viricel","year":"2015","unstructured":"Viricel, C., Ahmed, M. & Barakat, K. Human PD-1 binds differently to its human ligands: a comprehensive modeling study. J. Mol. Graph Model 57, 131\u2013142 (2015).","journal-title":"J. Mol. Graph Model"},{"key":"1537_CR35","unstructured":"WHO Classification of Tumours Editorial Board. Central Nervous System Tumours (5th ed., Vol. 6). International Agency for Research on Cancer (2021)."},{"key":"1537_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","volume":"6","author":"G Bajaj","year":"2017","unstructured":"Bajaj, G. et al. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacomet. Syst. Pharm. 6, 58\u201366 (2017).","journal-title":"CPT Pharmacomet. Syst. Pharm."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01537-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01537-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01537-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:03:25Z","timestamp":1787828605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01537-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01537-4","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.V.L. is a consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L, IO Biotech, Immunocore, Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR Ltd, Pierre Fabre, Regeneron. A.M.M. is a consultant advisor for BMS, MSD, Novartis, Pierre-Fabre, Roche and QBiotics. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"332"}}